Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models

Japanese Heart Journal
K Akiyama, K Hashimoto

Abstract

The properties of a class 1c antiarrhythmic drug, flecainide, were examined using 3 canine ventricular arrhythmia models: (1) digitalis-, (2) adrenaline- and (3) two-stage coronary ligation-induced arrhythmias. The minimum effective plasma concentration of flecainide was determined for each model. Flecainide suppressed the arrhythmias. The minimum effective plasma concentrations for arrhythmias induced by digitalis, adrenaline and 24 hr coronary ligation, were 0.9 +/- 0.2, 1.4 +/- 0.6, 1.5 +/- 0.4 mcg/ml, respectively (mean +/- SD, n = 6). These minimum effective plasma concentrations of flecainide were almost equal to the reported in vitro concentration that suppress the Na channels of isolated canine ventricular tissues. Thus, flecainide may suppress these arrhythmias by inhibiting the Na channels of cardiac cells.

Citations

Mar 16, 1993·European Journal of Pharmacology·A Haruno, K Hashimoto
Apr 1, 1994·Progress in Neurobiology·J R Elliott, A A Elliott
Oct 26, 2001·Japanese Journal of Pharmacology·A TakaharaK Hashimoto
Jan 4, 2005·European Journal of Pharmacology·Yoshinobu NagasawaKeitaro Hashimoto
Apr 6, 2007·Journal of Pharmacological Sciences·Keitaro Hashimoto
Apr 20, 2016·Sleep·Adeline DuchêneMathieu Charvériat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.